Free Trial
NASDAQ:NKTX

Nkarta (NKTX) Stock Price, News & Analysis

Nkarta logo
$3.23
+0.04 (+1.25%)
(As of 11/4/2024 ET)

About Nkarta Stock (NASDAQ:NKTX)

Key Stats

Today's Range
$3.14
$3.45
50-Day Range
$3.08
$6.51
52-Week Range
$1.90
$16.24
Volume
713,834 shs
Average Volume
1.14 million shs
Market Capitalization
$227.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.50
Consensus Rating
Buy

Company Overview

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Nkarta Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
55th Percentile Overall Score

NKTX MarketRank™: 

Nkarta scored higher than 55% of companies evaluated by MarketBeat, and ranked 513th out of 972 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nkarta has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nkarta has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Nkarta's stock forecast and price target.
  • Earnings Growth

    Earnings for Nkarta are expected to decrease in the coming year, from ($1.92) to ($1.98) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nkarta is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nkarta is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nkarta has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Nkarta's valuation and earnings.
  • Percentage of Shares Shorted

    14.77% of the outstanding shares of Nkarta have been sold short.
  • Short Interest Ratio / Days to Cover

    Nkarta has a short interest ratio ("days to cover") of 18.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nkarta has recently increased by 10.38%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nkarta does not currently pay a dividend.

  • Dividend Growth

    Nkarta does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.77% of the outstanding shares of Nkarta have been sold short.
  • Short Interest Ratio / Days to Cover

    Nkarta has a short interest ratio ("days to cover") of 18.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nkarta has recently increased by 10.38%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Nkarta has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Nkarta this week, compared to 2 articles on an average week.
  • Search Interest

    6 people have searched for NKTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nkarta insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.70% of the stock of Nkarta is held by insiders.

  • Percentage Held by Institutions

    80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nkarta's insider trading history.
Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

NKTX Stock News Headlines

Nkarta (NKTX) Stock: Looking For Upside
Nkarta to Participate in Upcoming Investor Conference
Urgent: This election is rigged
If you missed it, my emergency election broadcast is now available - but will be removed soon
Why Nkarta Stock Is Soaring Today
See More Headlines

NKTX Stock Analysis - Frequently Asked Questions

Nkarta's stock was trading at $6.60 at the beginning of the year. Since then, NKTX stock has decreased by 51.1% and is now trading at $3.23.
View the best growth stocks for 2024 here
.

Nkarta, Inc. (NASDAQ:NKTX) issued its earnings results on Tuesday, August, 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.15.

Nkarta (NKTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO.

Top institutional investors of Nkarta include SG Americas Securities LLC (0.04%), Bleakley Financial Group LLC (0.03%), Holistic Planning LLC (0.01%) and GAMMA Investing LLC (0.02%). Insiders that own company stock include Ra Capital Management, LP, Simeon George, Paul J Hastings, James Trager, David Shook, Alicia J Hager and Ralph Brandenberger.
View institutional ownership trends
.

Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nkarta investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/13/2024
Today
11/04/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NKTX
Fax
N/A
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.50
High Stock Price Target
$25.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+422.4%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

Net Income
$-117,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.56 per share

Miscellaneous

Free Float
64,420,000
Market Cap
$236.38 million
Optionable
Optionable
Beta
0.87
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:NKTX) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners